Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRT and Trastuzumab Emtansine in HER2+ Oligometastatic Breast Cancer
NCT06299852Recruiting
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
- Start
- Jul 2022
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Open-label trial of trastuzumab emtansine in breast cancer (2 arms), sponsored by N.N. Petrov National Medical Research Center of Oncology. Primary endpoint: Objective Response Rate at 3 months. Started Jul 2022; status: recruiting.
02
Drugs
trastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06299852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06299852.